SMS Co., Ltd. (SMSZF)
OTCMKTS
· Delayed Price · Currency is USD
8.56
0.00 (0.00%)
Apr 29, 2025, 4:00 PM EDT
SMS Co., Ltd. Revenue
In the fiscal year ending March 31, 2025, SMS Co., Ltd. had annual revenue of 60.95B JPY with 12.93% growth. SMS Co., Ltd. had revenue of 16.07B in the quarter ending March 31, 2025, with 9.93% growth.
Revenue
60.95B JPY
Revenue Growth
+12.93%
P/S Ratio
1.95
Revenue / Employee
14.55M JPY
Employees
4,188
Market Cap
794.41M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 60.95B | 6.98B | 12.93% |
| Mar 31, 2024 | 53.97B | 8.31B | 18.19% |
| Mar 31, 2023 | 45.67B | 6.77B | 17.40% |
| Mar 31, 2022 | 38.90B | 2.94B | 8.17% |
| Mar 31, 2021 | 35.96B | 820.00M | 2.33% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |